epocrates logo
epocrates logo
epocrates logo
  • 0

Herbs & Supplements

epocrates logo

Sign in to access our clinical decision support tools

Sign in Create Account

Formulary
No Formulary Selected

close

 

Select a medication above to begin.

luteina

lutein

Sections:

  • Entire Monograph
  • Reported Uses
  • Reported Doses
  • Cautions
  • Drug Interactions
  • Adverse Reactions
  • Synonyms
  • Other Info
  • Add to Interaction Check

Reported Uses

  • NOTE: see Herb & Supplement Effectiveness Rating Definitions table
  • age-related cognitive decline [Insufficient Evidence]
  • age-related macular degeneration [Possibly Effective]
  • Alzheimer disease [Insufficient Evidence]
  • amyotrophic lateral sclerosis [Insufficient Evidence]
  • asthenopia (eye strain) [Insufficient Evidence]
  • asthma [Insufficient Evidence]
  • bronchopulmonary dysplasia [Possibly Ineffective]
  • cancer prevention, breast [Insufficient Evidence]
  • cancer prevention, cervical [Insufficient Evidence]
  • cancer prevention, colorectal [Insufficient Evidence]
  • cancer prevention, esophageal [Insufficient Evidence]
  • cancer prevention, gastric [Insufficient Evidence]
  • cancer prevention, lung [Insufficient Evidence]
  • cancer prevention, pancreatic [Insufficient Evidence]
  • cardiovascular disease prevention [Insufficient Evidence]
  • cataracts [Possibly Effective]
  • central serous retinopathy [Insufficient Evidence]
  • child development [Insufficient Evidence]
  • choroideremia [Insufficient Evidence]
  • cognitive function [Insufficient Evidence]
  • depression [Insufficient Evidence]
  • diabetes [Insufficient Evidence]
  • diabetic retinopathy [Insufficient Evidence]
  • dry eye disease [Insufficient Evidence]
  • exercise-induced muscle soreness [Insufficient Evidence]
  • fracture [Insufficient Evidence]
  • glaucoma [Insufficient Evidence]
  • hyperlipidemia [Insufficient Evidence]
  • infertility in patients of childbearing potential [Insufficient Evidence]
  • intraventricular hemorrhage [Possibly Ineffective]
  • macular telangiectasia type 2 [Insufficient Evidence]
  • metabolic dysfunction-associated steatotic liver disease [Insufficient Evidence]
  • metabolic syndrome [Insufficient Evidence]
  • myopia [Insufficient Evidence]
  • necrotizing enterocolitis prevention [Possibly Ineffective]
  • non-Hodgkin lymphoma [Insufficient Evidence]
  • obesity [Insufficient Evidence]
  • Parkinson disease [Insufficient Evidence]
  • pre-eclampsia [Insufficient Evidence]
  • respiratory infections [Insufficient Evidence]
  • retinitis pigmentosa [Possibly Ineffective]
  • retinopathy of prematurity [Possibly Ineffective]
  • ulcerative colitis [Insufficient Evidence]
  • visual development [Insufficient Evidence]

Copyright © 2026. All Rights Reserved. Republication or redistribution, including by framing or similar means, is prohibited without the prior written consent of copyright holder.

Select a medication above to begin.

Help
FDA Reporting Form
 
Download Epocrates from the App Store Download Epocrates from the Play Store
About Us Features Business Solutions Help & Feedback
© 2026 epocrates, Inc.    Terms of Use Privacy Policy Editorial Policy Do Not Sell or Share My Information